Adjuvant Ribociclib With Endocrine Therapy in Hormone Receptor+/HER2- Intermediate Risk Early Breast Cancer
Status:
Withdrawn
Trial end date:
2025-11-17
Target enrollment:
Participant gender:
Summary
This is an international, multi-center, randomized, double-blinded, placebo-controlled
clinical study evaluating the efficacy and safety of ribociclib with endocrine therapy as an
adjuvant treatment in patients with hormone receptor-positive, HER2-negative, intermediate
risk breast cancer.